CRANBURY, N.J., Feb. 28, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (PTN), a biopharmaceutical company developing first-in-class medicines based on molecules that modulate the activity of the ...
Only FDA-Approved As-Needed Treatment For The Approximately 6 Million Premenopausal Women Who Suffer From Hypoactive Sexual Desire Disorder (HSDD) Vyleesi® has experienced 8 Consecutive Quarters of ...
Vyleesi is only the second drug to be approved for women with low sexual desire. We’ve long seen advertisements for drugs like Cialis or Viagra, which help to improve sexual performance in men with ...
Partnership will increase hypoactive sexual desire disorder (HSDD) awareness and expand access to Vyleesi via UpScriptHealth's Women's Health Platform CRANBURY, N.J., Aug. 7, 2023 /PRNewswire/ -- ...
WALTHAM, Mass., Oct. 11, 2019 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) announced that the data from its two pivotal, double-blind placebo-controlled Phase 3 trials (RECONNECT) and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results